Zdrowie i gospodarka · 12/08/2026
National Cancer Institute Seeks License for CRISPR Engineered Cancer Cell Line to Study Immunotherapy Strategies
The National Cancer Institute is seeking licensees for a CRISPR/Cas9-engineered MC38 B2m knockout murine colon cancer cell line, which models tumor resistance to PD-1/PD-L1 checkpoint blockade, to study alternative or combination immunotherapy strategies for cancers that evade conventional T-cell recognition.